Daniel Klaber
Family · Butler, KYNPI 1073002465
Payments from drug & device makers
Across 177 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$722
- Teva Pharmaceuticals USA, Inc.$352
- Bayer$305
- Axsome Therapeutics, Inc.$209
- Neurocrine Biosciences, Inc.$124
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$123
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,322100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,322 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 61 | $85,916 |
| OzempicSemaglutide | 76 | $72,731 |
| JardianceEmpagliflozin | 29 | $28,661 |
| XareltoRivaroxaban | 17 | $22,997 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 418 | $21,816 |
| EliquisApixaban | 29 | $21,495 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $20,706 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $16,270 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 59 | $12,283 |
| FarxigaDapagliflozin Propanediol | 12 | $11,323 |
| LinzessLinaclotide | 14 | $8,140 |
| MyrbetriqMirabegron | 12 | $7,271 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $4,806 |
| Ranolazine ErRanolazine | 15 | $3,198 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 45 | $3,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess | $722 | $94,05675 claims |
| Novo NordiskOzempic | $104 | $72,73176 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $87 | $36,97759 claims |
| Johnson & JohnsonXarelto | $29 | $22,99717 claims |
| PfizerEliquis | $46 | $21,49529 claims |
| Indivior Inc.Suboxone | $25 | $12,28359 claims |
| AstraZenecaFarxiga | $39 | $11,32312 claims |
| Astellas Pharma US IncMyrbetriq | $96 | $7,27112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.
Other family in Butler
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.